1 Unstoppable Healthcare Stock to Buy and Hold

HCA Healthcare reported Q4 2025 revenue of $19.5 billion, up 6.7%, and adjusted EPS of $8.01, up 28.8%. The company guided fiscal 2026 revenue to $76.5–$80.0 billion (midpoint ≈3.5% year-over-year growth) but highlighted regulatory uncertainty after enhanced premium tax credits expired, which likely dampens near-term demand. Management cites AI-driven initiatives and ongoing market-share gains as drivers of improved patient outcomes and long-term growth amid aging demographics. The stock is up roughly 7% YTD 2026, and while guidance is modest, strong profitability supports a constructive longer-term investment case.

Analysis

Market structure: HCA (HCA) benefits from scale, diversified sites-of-care and ability to capture market share as smaller hospitals struggle with payer mix and labor inflation. Expiration of enhanced ACA premium tax credits is an immediate headwind to insured volume; HCA’s guidance midpoint (~3.5% revenue growth) implies resilience but also a re-pricing of benign consensus. Large payers (UNH/CVS) are mixed beneficiaries — less acute volume but lower uncompensated care; private regional operators (e.g., CYH) are most exposed to margin compression.

Risk assessment: Tail risks include a sudden legislative rollback/Medicare reimbursement cuts or a large CMS policy change that trims APC/DRG rates (low-probability but >30% downside to EPS in a stress year). Near-term (days–weeks) risk: headline-driven volatility around regulatory developments and quarterly calls; medium-term (3–9 months): payer negotiations and subsidy decisions; long-term (2–5 years): demographic-driven demand plus 100–200 bps potential margin improvement from AI and scale. Hidden dependency: continued physician alignment and success of AI investments require upfront CAPEX that can depress near-term free cash flow.

Trade implications: Tactical: establish a 2–3% long HCA position on weakness (buy into any pullback >8% from current levels) with a 12–15% stop; add 9–12 month call spreads (HCA +12%/+30% strikes) sized to 1–1.5% notional for upside leverage. Pair trade: long HCA vs short CYH (short size 50–70% of long) to capture consolidation spread. Hedging: buy 9–12 month HCA puts 20% OTM (cost <1.5% of position) or sell short-dated covered calls if long.

Contrarian angles: Consensus underestimates margin recovery from AI and scale (potential +100–200 bps EBITDA over 24 months) and overestimates permanent demand hit from subsidy expiry. If Congress restores credits within 30–90 days, expect accelerated re-rating: trim hedges and target +20–30% price appreciation within 6–12 months. Conversely, if HCA reports accelerating admissions and payor mix stabilization, initiate scale-up to 4–5% portfolio weight; if admissions weaken another 3–4% sequentially, reduce exposure to zero.

Key Decisions for Investors

• Establish a 2–3% net long position in HCA (NYSE: HCA) within the next 2–6 weeks; use a 12–15% stop-loss and a 12–18 month target horizon aiming for a 20–30% upside if admissions and margins stabilize.
• Enter a pair trade: long HCA (size X) vs short Community Health Systems (CYH) at 50–70% of HCA size to exploit scale/credit advantages; hold 6–12 months and rebalance if spread narrows <5% absolute.
• Buy a defined-risk call spread on HCA (9–12 month expiry, ~12%–30% OTM strikes) sized to 1–1.5% of portfolio to capture upside while capping premium, and simultaneously purchase 9–12 month HCA 20% OTM puts (size ~0.5–1%) as tail-hedge against regulatory shock.
• Reduce small-cap/regional hospital exposure by ~50% now and rotate 1–2% portfolio weight into large cap healthcare services (HCA, UNH) over 30 days; increase cash if HCA falls >10% on regulatory headlines and add to long at that level.
• Monitor three binary catalysts over next 30–90 days: (1) Congressional action on ACA premium tax credits (if restored, trim hedges and add to HCA), (2) next CMS inpatient/outpatient payment notices and HCA’s Q1 admissions/mix data — if admissions decline sequentially >3% add hedges, (3) material AI/CAPEX guidance from HCA — if management quantifies >100 bps margin uplift, scale exposure to 4–5%.